Insider transactions

Albert Cha

CIK 1397906 · last filed 2023-09-28

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$44.27M
Companies
7
Total Filings
32
Lifetime Open-Market Net
$41.68M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

KALV price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
505 HAMILTON AVENUE, SUITE 200
PALO ALTO, CA 94301
Related Filers
Biohaven Pharmaceutical Holding Co Ltd. — 4 joint filings, latest 2018-05-03
Edgar Engleman — 2 joint filings, latest 2014-11-20
Vivo Ventures Fund V, L.P. — 2 joint filings, latest 2014-11-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KalVista Pharmaceuticals, Inc. (KALV) Delisted Director 1,144,179 $27.00 $30.89M $21.85M 13 2023-09-28
BHVN Director 2,049,545 $14.28 $29.27M $7.99M 3 2018-05-03
VYNE Therapeutics Inc. (MNLO) Delisted Director 2,606,982 — — $5.00M 1 2018-01-29
ACRS Director 4,191,397 $3.58 $15.01M $5.15M 3 2016-07-01
Sierra Oncology, Inc. (DNAI) Delisted Director 2,064,308 — — $3.74M 1 2015-07-21
ALBIREO PHARMA, INC. (BIOD) Delisted Director 51,799 — — -$2.05M 3 2008-03-04
BIOFORM MEDICAL INC (BFRM) Delisted Director 87,410 — — $0 1 2007-11-14

Recent Filings · Page 3 of 4

32 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2017-05-09 BHVN Mixed +1,976,818 $7.99M EDGAR
2017-03-27 KalVista Pharmaceuticals, Inc. (KALV) Delisted Grant (A) — $0 EDGAR
2016-07-01 ACRS Grant (A) — $0 EDGAR
2015-10-13 ACRS Mixed +3,888,191 $5.00M EDGAR
2015-10-09 ACRS Buy (P) +13,352 $146.9K EDGAR
2015-07-21 Sierra Oncology, Inc. (DNAI) Delisted Mixed +2,438,270 $4.31M EDGAR
2015-04-27 — Mixed +4,204,562 $5.06M
2015-04-14 — Mixed +4,204,564 $5.06M
2008-03-04 ALBIREO PHARMA, INC. (BIOD) Delisted Grant (A) — $0 EDGAR
2008-02-14 ALBIREO PHARMA, INC. (BIOD) Delisted Sell (S) −132,000 -$2.05M EDGAR
Showing 21–30 of 32
Page 3 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.